These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 33573405)

  • 1. Comparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS).
    Truong CB; Durham SH; Qian J
    Expert Opin Drug Saf; 2021 May; 20(5):603-609. PubMed ID: 33573405
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute kidney injury with intravenous colistin sulfate compared with polymyxin B in critically ill patients: A real-world, retrospective cohort study.
    Yang QJ; Xiang BX; Song MH; Yang CY; Liang JH; Xie YL; Zuo XC
    Pharmacotherapy; 2024 Aug; 44(8):631-641. PubMed ID: 39046197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center.
    Akajagbor DS; Wilson SL; Shere-Wolfe KD; Dakum P; Charurat ME; Gilliam BL
    Clin Infect Dis; 2013 Nov; 57(9):1300-3. PubMed ID: 23840000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).
    Patek TM; Teng C; Kennedy KE; Alvarez CA; Frei CR
    Drug Saf; 2020 Jan; 43(1):17-22. PubMed ID: 31691256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.
    Crass RL; Rutter WC; Burgess DR; Martin CA; Burgess DS
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymyxin B vs. colistin: the comparison of neurotoxic and nephrotoxic effects of the two polymyxins.
    Aysert-Yildiz P; Özgen-Top Ö; Şentürk AF; Kanik S; Özger HS; Dizbay M
    BMC Infect Dis; 2024 Aug; 24(1):862. PubMed ID: 39187812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Battle of polymyxin induced nephrotoxicity: Polymyxin B versus colistin.
    Ballı FN; Ekinci PB; Kurtaran M; Kara E; Dizman GT; Sönmezer MÇ; Hayran M; Demirkan K; Metan G
    Int J Antimicrob Agents; 2024 Feb; 63(2):107035. PubMed ID: 37979889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies.
    Oliota AF; Penteado ST; Tonin FS; Fernandez-Llimos F; Sanches AC
    Diagn Microbiol Infect Dis; 2019 May; 94(1):41-49. PubMed ID: 30635223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?
    Zavascki AP; Nation RL
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
    Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
    Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.
    Rigatto MH; Oliveira MS; Perdigão-Neto LV; Levin AS; Carrilho CM; Tanita MT; Tuon FF; Cardoso DE; Lopes NT; Falci DR; Zavascki AP
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2443-9. PubMed ID: 26856846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of nephrotoxicity of Colistin with Polymyxin B administered in currently recommended doses: a prospective study.
    Aggarwal R; Dewan A
    Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):15. PubMed ID: 29571295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.
    Nation RL; Li J; Cars O; Couet W; Dudley MN; Kaye KS; Mouton JW; Paterson DL; Tam VH; Theuretzbacher U; Tsuji BT; Turnidge JD
    Lancet Infect Dis; 2015 Feb; 15(2):225-34. PubMed ID: 25459221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined nephrotoxicity of Polymyxins and Vancomycin: a study on adverse event reporting for monotherapy versus combinations using the FDA adverse event reporting system (FAERS).
    Zhan R; Lin J; Dai M; Ji B; He X; Jiang Z
    Expert Opin Drug Saf; 2024 Oct; ():1-6. PubMed ID: 39391997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).
    Tsuji BT; Pogue JM; Zavascki AP; Paul M; Daikos GL; Forrest A; Giacobbe DR; Viscoli C; Giamarellou H; Karaiskos I; Kaye D; Mouton JW; Tam VH; Thamlikitkul V; Wunderink RG; Li J; Nation RL; Kaye KS
    Pharmacotherapy; 2019 Jan; 39(1):10-39. PubMed ID: 30710469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.
    Phe K; Lee Y; McDaneld PM; Prasad N; Yin T; Figueroa DA; Musick WL; Cottreau JM; Hu M; Tam VH
    Antimicrob Agents Chemother; 2014 May; 58(5):2740-6. PubMed ID: 24566187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system.
    Fan Q; Ma J; Zhang B; Li Q; Liu F; Zhao B
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):655-662. PubMed ID: 33001273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis.
    Vardakas KZ; Falagas ME
    Int J Antimicrob Agents; 2017 Feb; 49(2):233-238. PubMed ID: 27686609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. To B or not to B, that is the question: is it time to replace colistin with polymyxin B?
    Kassamali Z; Danziger L
    Pharmacotherapy; 2015 Jan; 35(1):17-21. PubMed ID: 25346395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.